{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-I9CLKMOC/51e1f69c-1eab-4d52-b2c1-1e1e6941670f/PDF","dcterms:extent":"543 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-I9CLKMOC/b9cc0aab-4add-4085-89a6-749b30fa6b0a/TEXT","dcterms:extent":"44 KB"}],"edm:TimeSpan":{"@rdf:about":"1992-2025","edm:begin":{"@xml:lang":"en","#text":"1992"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-I9CLKMOC","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-FNIFVE9S"},{"@xml:lang":"sl","#text":"Radiology and oncology (Ljubljana)"}],"dcterms:issued":"2022","dc:creator":["Devjak, Rok","Edelbaher, Natalija","Janžič, Urška","Jerič, Tina","Osrajnik, Ilonka","Turnšek, Nina","Unk, Mojca","Vidovič, Dušanka"],"dc:contributor":"Turnšek, Nina","dc:format":[{"@xml:lang":"sl","#text":"številka:3"},{"@xml:lang":"sl","#text":"letnik:56"},{"@xml:lang":"sl","#text":"str. 371-379"}],"dc:identifier":["DOI:10.2478/raon-2022-0025","COBISSID_HOST:118793219","ISSN:1318-2099","URN:URN:NBN:SI:doc-I9CLKMOC"],"dc:language":"en","dc:publisher":{"@xml:lang":"sl","#text":"Association of Radiology and Oncology"},"dc:subject":[{"@xml:lang":"en","#text":"epidermal growth factor receptor"},{"@xml:lang":"sl","#text":"klinične študije"},{"@xml:lang":"en","#text":"lung cancer"},{"@xml:lang":"sl","#text":"nedrobnocelični rak"},{"@xml:lang":"en","#text":"non-small cell lung cancer"},{"@xml:lang":"sl","#text":"rak pljuč"},{"@xml:lang":"en","#text":"real-world study"},{"@xml:lang":"sl","#text":"receptor epidermalnega rastnega faktorja"}],"dcterms:temporal":{"@rdf:resource":"1992-2025"},"dc:title":{"@xml:lang":"sl","#text":"Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients| treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study|"},"dc:description":{"@xml:lang":"sl","#text":"Background. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR mutation-positive (EGFRm) non-small cell lung cancer (NSCLC). However, routine clinical practice is different between countries/institutions. Patients and methods. The REFLECT study (NCT04031898) is a retrospective medical chart review that explored real-life treatment and outcomes of EGFRm NSCLC patients receiving first-line (1L) first-/second-generation (1G/2G) EGFR TKIs in 8 countries. This study included adult patients with documented advanced/metastatic EGFRm NSCLC with 1L 1G/2G EGFR TKIs initiated between Jan 2015 – Jun 2018. We reviewed data on clinical characteristics, treatments, EGFR/T790M testing patterns, and survival outcomes. Here, we report data from 120 medical charts in 3 study sites from Slovenia. Results. The Slovenian cohort (median age 70 years, 74% females) received 37% erlotinib, 32% afatinib, 31% gefitinib. At the time of data collection, 94 (78%) discontinuations of 1L TKI, and 89 (74%) progression events on 1L treatment were reported. Among patients progressing on 1L, 73 (82%) were tested for T790M mutation yielding 50 (68%) positive results, and 62 (85%) received 2L treatment. 82% of patients received osimertinib. Attrition rate between 1L and 2L was 10%. The median (95% CI) real-world progression free survival on 1L EGFR TKIs was 15.6 (12.6, 19.2) months; median overall survival (95% CI) was 28.9 (25.0, 34.3) months. Conclusions. This real-world study provides valuable information about 1G/2G EGFR TKIs treatment outcomes and attrition rates in Slovenian EGFRm NSCLC patients. The reduced attrition rate and improved survival outcomes empha-size the importance of 1L treatment decision"},"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-I9CLKMOC","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-I9CLKMOC"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-I9CLKMOC/51e1f69c-1eab-4d52-b2c1-1e1e6941670f/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Društvo radiologije in onkologije"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-I9CLKMOC/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-I9CLKMOC"}}}}